Advertisements


Why Salem Health diverted ambulances last week and could do so again

Salem Health has been operating at more than 100% capacity for about a year......»»

Category: topSource: bizjournalsAug 5th, 2022

Oregon Bungles New Addiction Recovery Program Tied To Decriminalization

Oregon Bungles New Addiction Recovery Program Tied To Decriminalization Thanks to mismanagement and naive assumptions about the propensities of drug abusers, a new public health program associated with Oregon's decriminalization of drugs is falling flat on its face.  The state has only managed to spend a small fraction of a $305 million budget meant to expand substance abuse and recovery services. The money, which comes from cannabis tax revenue, was diverted from schools, mental health services and state police but now much of it sits idle.  As OregonLive reports:  So far not a single new treatment bed has been funded since Measure 110′s passage to decriminalize the possession of small amounts of heroin and other street drugs and set up a system to refer and treat those suffering from addiction. Ballot Measure 110 was approved by Oregonians in 2020, making it the first state to decriminalize possession of personal amounts of heroin, cocaine, meth, LSD, ecstasy, oxycodone and other drugs. Under decriminalization, which took effect on Feb. 1, 2021, people found in possession receive a citation—akin to a traffic ticket—rather than jail time.  Consistent with viewing addiction as a health problem and not a criminal justice issue, Measure 110 aspired to create a robust statewide network of resources for those with substance abuse problems. It isn't even close to materializing.   Responsibility for selecting service providers and distributing hundreds of millions of dollars falls to a citizen-led council. The law requires that, among others, the council must include a social worker, a physician, "an evidence-based substance abuse disorder provider," an academic researcher and "at least two people who suffered or suffer from a substance abuse disorder." That's not exactly stacking the deck for success in overseeing a multifaceted, $300 million government program serving towns, cities and counties all over the state.   The council has been overwhelmed by applications from some 330 organizations eager for state money, and grant timelines have been revised multiple times. Council member Caroline Cruz described a recent meeting as "total chaos." Another council member, Morgan Godvin, told state officials, "I don’t know grant-making. That was [the Oregon Health Authority's] duty, but you did not fulfill it and the goalposts just keep moving. I have whiplash trying to keep up with this, but at no point do I hear an acceptance of responsibility from OHA saying 'we dropped the ball'.” Buried under the deluge of grant requests, the council opted to start by awarding grants to sparsely populated eastern Oregon counties, rather than to Portland, Salem and other major population centers. That doesn't strike anyone as sound triage for a health emergency.   So far, just $40 million of the $305 million have been allocated for the 2021-23 biennium. At this pace, the council won't be even halfway finished making allocations for this biennium before the next one starts.   Distancing itself from the fiasco, the office of Governor Kate Brown told The Oregonian that the governor doesn't appoint the council or oversee its work, directing questions to the OHA.  Finger-pointing abounded in Salem this week. Mike Mike Marshall, executive director of Oregon Recovers, a statewide coalition focused on addiction, characterized the rollout as a "debacle" and blamed both OHA and the governor.  The shoveling of money at addiction treatment isn't the only aspect of the program that's faltering. So too is a feature meant to encourage cited possessors to avail themselves of help. In Oregon, the maximum penalty under a drug possession citation is $100, but that's waived if the individual calls a health assessment hotline to complete a substance abuse disorder screening. So far, police across Oregon have issued roughly 2,000 citations and only 91 people—something like 4.5%—have called the hotline.  Though reporting doesn't make it clear, it's not hard to imagine that most of the others didn't bother paying the citation either.  Meanwhile, in a Thursday hearing of Oregon's House behavioral health committee that focused on the botched rollout, Republican representative Lily Morgan, of the southern Oregon town of Grants Pass, pointed to rising overdoses as she expressed skepticism about Oregon's new approach. “Director, you’ve mentioned a couple of times that you’re waiting to see, and yet we have overdoses increasing at drastic rates, in my community a 700% increase in overdoses and a 120% increase in deaths,” said Morgan, addressing Oregon Behavioral Health Director Steve Allen. “How long do we wait before we have an impact that we’re saving lives?” It may seem counterintuitive, but much of that spike springs from the fact that, while possession of drugs has been decriminalized, the sale of drugs in Oregon is still illegal. That leaves users vulnerable to the particular perils of black market drugs.  Consistent with that reality, Allen attributed much of the increase in overdoses and overdose deaths to a recent wave of both methamphetamine and illegal pills laced with fentanyl, an opioid that can be deadly in small doses. Allen may not have made this point, but we will: In a competitive, fully legal drug market where users (and their estates) could use courts to hold professional producers accountable for failing to provide products with clearly delineated dosages and uniform ingredients, overdoses would plummet.     Tyler Durden Sun, 06/05/2022 - 18:00.....»»

Category: personnelSource: nytJun 5th, 2022

Watch Live: President Biden Explains Why Vaxx"d Breakthroughs Are All The Unvaxx"d Fault

Watch Live: President Biden Explains Why Vaxx'd Breakthroughs Are All The Unvaxx'd Fault With cases surging and his agenda collapsing, it's time for President Biden to face the public. Of coourse, the president and his team have already leaked all the important details of what he's prepared to say this afternoon to the press, and we reported on them this morning. As we said, the administration is preparing to roll out a new federal plan to swiftly get 500M tests into the hands of Americans, and place army-trained medical personnel into vulnerable hospitals across the country, among other measures. But what's been especially notable about recent developments (especially for anybody who saw the tripled-vaxxed Jim Cramer's rant on CNBC Tuesday morning) is that the White House appears to finally be backing away from its strategy of blaming all the nation's troubles on the unvaccinated, and instead acknowledging that everybody will likely get sick in the end anyway - but we have plenty of vaccines and drugs that can be taken to try and deal with that, for those who are at risk. The announcement notably comes as the FDA prepares to approve new pills from Merck and Pfizer that treat patients already sickened with COVID, patients who are specifically deemed to be high risk. But we wonder: will this narrative shift provoke the press into pressing Biden to explain whether all these breakthrough infections are still somehow the unvaccinated population's fault? He will finally address the public Tuesday, after yet another White House press briefing, where his chief spokeswoman Jen Psaki has absorbed all of the blows from the press about the collapse of Biden's 'Build Back Better' Agenda. In addition to the tests, here's a breakdown of the other measures being ordered by Biden (text courtesy of the New York Times): Biden intends to direct his defense secretary, Lloyd J. Austin III, to “ready an additional 1,000 service members — military doctors, nurses, paramedics and other medical personnel — to deploy to hospitals during January and February, as needed,” according to a fact sheet prepared by the White House. At the same time, Biden will announce that six federal emergency response teams, with more than 100 health professionals and paramedics, will deploy immediately to six states: Michigan, Indiana, Wisconsin, Arizona, New Hampshire and Vermont. Already, 300 federal medical workers have been deployed since Omicron was discovered in late November. Biden will also direct the Federal Emergency Management Agency to work with hospitals across the country to make plans to expand capacity. FEMA will also stand up new pop-up vaccination clinics, the officials said, to handle hundreds of additional vaccinations per week. The government is also sending ventilators to the states - last week, officials said, it sent 330 - and will have hundreds of ambulances and emergency medical teams, overseen by FEMA, at the ready "so that if one hospital fills up, they can transport patients to open beds in other facilities," according to the fact sheet. It was not clear who would staff those teams, but the fact sheet said that even now, "30 paramedics are heading to New Hampshire, 30 to Vermont and 20 to Arizona, and 30 ambulances are headed to New York and eight to Maine." Readers can watch live below: (due to start at 1430ET) Meanwhile, Democrats are reportedly freaking out over Sen. Joe Manchin's decision to nuke Biden's "Build Back Better" agenda. So we expect reporters to ask a few more questions about that, despite the administration's attempts to wait out the press and letting reporters confront Psaki with all the hard questions. Tyler Durden Tue, 12/21/2021 - 14:25.....»»

Category: blogSource: zerohedgeDec 21st, 2021

Biden Plans To Distribute 500 Million Tests As Omicron Variant Overwhelms Most Vaccinated States

Biden Plans To Distribute 500 Million Tests As Omicron Variant Overwhelms Most Vaccinated States Last night, with the number of new COVID cases surging across the US, the CDC revealed that the number of new COVID cases caused by the omicron variant has already grown to 73% during the last week, up from the low teens a week ago, and less than 1% the week of the Thanksgiving holiday, when evidence of the new variant with some 50 mutations to help it avoid vaccine and natural immunity was first shared with the WHO. But in the US, at least, one of the most surprising aspects of this new wave is the fact that the states with the highest vaccination rates are seeing the biggest surge in new cases. This includes - but isn't limited to - New York, New Jersey and the six New England states, CT, MA, NH, VT, MA and RI. A few days ago, the RI chapter of the American College of Emergency Medicine warned in a letter to the governor and the top public health official that the hospital system in the state is "currently collapsing". In Maine, and a handful of other more populous states, the National Guard has been called in to help with hospital staffing shortages. And just last night, the NHL became the first US pro sports league to delay all play across all its teams due to the rising COVID numbers, although game cancellations have afflicted the NFL and NBA. President Biden is set to address the public Tuesday and lay out his plans to respond to the latest COVID "emergency" not with lockdowns and new restrictions, but with plans to get more COVID tests into the hands of the public. Instead, he will announce a sweeping plan to deploy 1,000 military medical professionals to help at overburdened hospitals, setting up new federal testing sites, deploying hundreds of federal vaccinators and buying 500MM rapid tests to distribute free to the public. According to the NYT, which published the news promptly at 0500ET, the measures were outlined to reporters Monday night by two senior administration officials who spoke on condition of anonymity, likely under the conditions of an embargo - news business jargon for when a story is leaked with the explicit agreement that reporters will wait until a given time to publish.  The 500MM tests that the administration intends to purchase will not be available until January, adding that the federal government intends to create a website where people can request that tests be sent to their homes, free of charge. It was not immediately clear where the tests would come from. If this sounds like a repeat, or a do-over, of the president's unveiling of his big winter plan to fight the pandemic a few weeks ago, that's largely because it is. Albeit with a different set of more popular (and more costly) measures that doesn't rely so much on the OSHA vaccination mandate that has been held up in the courts. In addition to the tests, here's a breakdown of the other measures being ordered by Biden (text courtesy of the NYT): Biden intends to direct his defense secretary, Lloyd J. Austin III, to “ready an additional 1,000 service members — military doctors, nurses, paramedics and other medical personnel — to deploy to hospitals during January and February, as needed,” according to a fact sheet prepared by the White House. At the same time, Biden will announce that six federal emergency response teams, with more than 100 health professionals and paramedics, will deploy immediately to six states: Michigan, Indiana, Wisconsin, Arizona, New Hampshire and Vermont. Already, 300 federal medical workers have been deployed since Omicron was discovered in late November. Biden will also direct the Federal Emergency Management Agency to work with hospitals across the country to make plans to expand capacity. FEMA will also stand up new pop-up vaccination clinics, the officials said, to handle hundreds of additional vaccinations per week. The government is also sending ventilators to the states - last week, officials said, it sent 330 - and will have hundreds of ambulances and emergency medical teams, overseen by FEMA, at the ready "so that if one hospital fills up, they can transport patients to open beds in other facilities," according to the fact sheet. It was not clear who would staff those teams, but the fact sheet said that even now, "30 paramedics are heading to New Hampshire, 30 to Vermont and 20 to Arizona, and 30 ambulances are headed to New York and eight to Maine." Per the NYT, the new Biden plan "has a more urgent tone than the winter pandemic strategy that Mr. Biden announced three weeks ago at the National Institutes of Health, just days after the new variant was discovered in South Africa." At the time, Biden promised that the 150MM Americans with private health insurance would be able to get reimbursed for at-home COVID tests starting in mid-January, and that his administration would improve access to booster shots and impose new testing requirements for international travelers. Unfortunately for the president, even the NYT is criticizing Biden's last plan for relying too heavily on vaccination as its "central strategy." But that plan — and Mr. Biden’s broader response to the Omicron variant — has drawn criticism from public health experts, who say the president has focused too heavily on vaccination as his central strategy. Many have called on him to be more aggressive about testing as a means of slowing the variant’s spread — including possibly sending rapid tests to the homes of every American, free of charge. Yesterday, the White House Press Secretary Jen Psaki insisted that lockdowns are no longer being considered as part of the federal response to the pandemic, and the Administration has stopped short of asking Americans to cancel holiday travel plans, which has elicited another round of warnings from the 'experts'. Some have warned that Biden is facing a "viral blizzard" that could be a major test for his presidency in the coming weeks. The US also reported its first confirmed omicron related death overnight, identified only as an unvaccinated man in Texas. But there's one issue the media hasn't really addressed: how come all the most heavily vaccinated states are also the ones seeing the biggest surge in cases and hospitalizations (which, also, have been less severe than the peak of last year's winter surge). Tyler Durden Tue, 12/21/2021 - 07:00.....»»

Category: blogSource: zerohedgeDec 21st, 2021

Babies are increasingly dying of syphilis in the US - but it"s 100% preventable

Babies with syphilis may have deformed bones, damaged brains, and struggle to hear, see, or breathe. A newborn baby rests at the Ana Betancourt de Mora Hospital in Camaguey, Cuba, on June 19, 2015. Alexandre Meneghini/Reuters The number of US babies born with syphilis quadrupled from 2015 to 2019. Babies with syphilis may have deformed bones, damaged brains, and struggle to hear, see, or breathe. Routine testing and penicillin shots for pregnant women could prevent these cases. This story was originally published by ProPublica, a Pulitzer Prize-winning investigative newsroom, in collaboration with NPR News. Sign up for The Big Story newsletter to receive stories like this one in your inbox.When Mai Yang is looking for a patient, she travels light. She dresses deliberately - not too formal, so she won't be mistaken for a police officer; not too casual, so people will look past her tiny 4-foot-10 stature and youthful face and trust her with sensitive health information. Always, she wears closed-toed shoes, "just in case I need to run."Yang carries a stack of cards issued by the Centers for Disease Control and Prevention that show what happens when the Treponema pallidum bacteria invades a patient's body. There's a photo of an angry red sore on a penis. There's one of a tongue, marred by mucus-lined lesions. And there's one of a newborn baby, its belly, torso and thighs dotted in a rash, its mouth open, as if caught midcry.It was because of the prospect of one such baby that Yang found herself walking through a homeless encampment on a blazing July day in Huron, California, an hour's drive southwest of her office at the Fresno County Department of Public Health. She was looking for a pregnant woman named Angelica, whose visit to a community clinic had triggered a report to the health department's sexually transmitted disease program. Angelica had tested positive for syphilis. If she was not treated, her baby could end up like the one in the picture or worse - there was a 40% chance the baby would die.Yang knew, though, that if she helped Angelica get treated with three weekly shots of penicillin at least 30 days before she gave birth, it was likely that the infection would be wiped out and her baby would be born without any symptoms at all. Every case of congenital syphilis, when a baby is born with the disease, is avoidable. Each is considered a "sentinel event," a warning that the public health system is failing.The alarms are now clamoring. In the United States, more than 129,800 syphilis cases were recorded in 2019, double the case count of five years prior. In the same time period, cases of congenital syphilis quadrupled: 1,870 babies were born with the disease; 128 died. Case counts from 2020 are still being finalized, but the CDC has said that reported cases of congenital syphilis have already exceeded the prior year. Black, Hispanic, and Native American babies are disproportionately at risk.There was a time, not too long ago, when CDC officials thought they could eliminate the centuries-old scourge from the United States, for adults and babies. But the effort lost steam and cases soon crept up again. Syphilis is not an outlier. The United States goes through what former CDC director Tom Frieden calls "a deadly cycle of panic and neglect" in which emergencies propel officials to scramble and throw money at a problem - whether that's Ebola, Zika, or COVID-19. Then, as fear ebbs, so does the attention and motivation to finish the task.The last fraction of cases can be the hardest to solve, whether that's eradicating a bug or getting vaccines into arms, yet too often, that's exactly when political attention gets diverted to the next alarm. The result: The hardest to reach and most vulnerable populations are the ones left suffering, after everyone else looks away.Yang first received Angelica's lab report on June 17. The address listed was a P.O. box, and the phone number belonged to her sister, who said Angelica was living in Huron. That was a piece of luck: Huron is tiny; the city spans just 1.6 square miles. On her first visit, a worker at the Alamo Motel said she knew Angelica and directed Yang to a nearby homeless encampment. Angelica wasn't there, so Yang returned a second time, bringing one of the health department nurses who could serve as an interpreter.They made their way to the barren patch of land behind Huron Valley Foods, the local grocery store, where people took shelter in makeshift lean-tos composed of cardboard boxes, scrap wood, and scavenged furniture, draped with sheets that served as ceilings and curtains. Yang stopped outside one of the structures, calling a greeting."Hi, I'm from the health department, I'm looking for Angelica."The nurse echoed her in Spanish.Angelica emerged, squinting in the sunlight. Yang couldn't tell if she was visibly pregnant yet, as her body was obscured by an oversized shirt. The two women were about the same age: Yang 26 and Angelica 27. Yang led her away from the tent, so they could speak privately. Angelica seemed reticent, surprised by the sudden appearance of the two health officers. "You're not in trouble," Yang said, before revealing the results of her blood test.Angelica had never heard of syphilis."Have you been to prenatal care?"Angelica shook her head. The local clinic had referred her to an obstetrician in Hanford, a 30-minute drive away. She had no car. She also mentioned that she didn't intend to raise her baby; her two oldest children lived with her mother, and this one likely would, too.Yang pulled out the CDC cards, showing them to Angelica and asking if she had experienced any of the symptoms illustrated. No, Angelica said, her lips pursed with disgust."Right now you still feel healthy, but this bacteria is still in your body," Yang pressed. "You need to get the infection treated to prevent further health complications to yourself and your baby."The community clinic was just across the street. "Can we walk you over to the clinic and make sure you get seen so we can get this taken care of?"Angelica demurred. She said she hadn't showered for a week and wanted to wash up first. She said she'd go later.Yang tried once more to extract a promise: "What time do you think you'll go?""Today, for sure."The CDC tried and failed to eradicate syphilis - twiceSyphilis is called The Great Imitator: It can look like any number of diseases. In its first stage, the only evidence of infection is a painless sore at the bacteria's point of entry. Weeks later, as the bacteria multiplies, skin rashes bloom on the palms of the hands and bottoms of the feet. Other traits of this stage include fever, headaches, muscle aches, sore throat, and fatigue. These symptoms eventually disappear and the patient progresses into the latent phase, which betrays no external signs. But if left untreated, after a decade or more, syphilis will reemerge in up to 30% of patients, capable of wreaking horror on a wide range of organ systems. Marion Sims, president of the American Medical Association in 1876, called it a "terrible scourge, which begins with lamb-like mildness and ends with lion-like rage that ruthlessly destroys everything in its way."The corkscrew-shaped bacteria can infiltrate the nervous system at any stage of the infection. Yang is haunted by her memory of interviewing a young man whose dementia was so severe that he didn't know why he was in the hospital or how old he was. And regardless of symptoms or stage, the bacteria can penetrate the placenta to infect a fetus. Even in these cases the infection is unpredictable: Many babies are born with normal physical features, but others can have deformed bones or damaged brains, and they can struggle to hear, see, or breathe.From its earliest days, syphilis has been shrouded in stigma. The first recorded outbreak was in the late 15th century, when Charles VIII led the French army to invade Naples. Italian physicians described French soldiers covered with pustules, dying from a sexually transmitted disease. As the affliction spread, Italians called it the French Disease. The French blamed the Neopolitans. It was also called the German, Polish, or Spanish disease, depending on which neighbor one wanted to blame. Even its name bears the taint of divine judgement: It comes from a 16th-century poem that tells of a shepherd, Syphilus, who offended the god Apollo and was punished with a hideous disease.By 1937 in America, when former Surgeon General Thomas Parran wrote the book "Shadow on the Land," he estimated some 680,000 people were under treatment for syphilis; about 60,000 babies were being born annually with congenital syphilis. There was no cure, and the stigma was so strong that public-health officials feared even properly documenting cases.Thanks to Parran's ardent advocacy, Congress in 1938 passed the National Venereal Disease Control Act, which created grants for states to set up clinics and support testing and treatment. Other than a short-lived funding effort during World War I, this was the first coordinated federal push to respond to the disease.Around the same time, the Public Health Service launched an effort to record the natural history of syphilis. Situated in Tuskegee, Alabama, the infamous study recruited 600 black men. By the early 1940s, penicillin became widely available and was found to be a reliable cure, but the treatment was withheld from the study participants. Outrage over the ethical violations would cast a stain across syphilis research for decades to come and fuel generations of mistrust in the medical system among Black Americans that continues to this day. People attend a ceremony near Tuskegee, Alabama, on April 3, 2017, to commemorate the roughly 600 men who were subjects in the Tuskegee syphilis study. Jay Reeves/AP Photo With the introduction of penicillin, cases began to plummet. Twice, the CDC has announced efforts to wipe out the disease - once in the 1960s and again in 1999.In the latest effort, the CDC announced that the United States had "a unique opportunity to eliminate syphilis within its borders," thanks to historically low rates, with 80% of counties reporting zero cases. The concentration of cases in the South "identifies communities in which there is a fundamental failure of public health capacity," the agency noted, adding that elimination - which it defined as fewer than 1,000 cases a year - would "decrease one of our most glaring racial disparities in health."Two years after the campaign began, cases started climbing, first among gay men and, later, heterosexuals. Cases in women started accelerating in 2013, followed shortly by increasing numbers of babies born with syphilis. The reasons for failure are complex: People relaxed safer sex practices after the advent of potent HIV combination therapies, increased methamphetamine use drove riskier behavior, and an explosion of online dating made it hard to track and test sexual partners, according to Ina Park, medical director of the California Prevention Training Center at the University of California San Francisco.But federal and state public-health efforts were hamstrung from the get-go. In 1999, the CDC said it would need about $35 million to $39 million in new federal funds annually for at least five years to eliminate syphilis. The agency got less than half of what it asked for, according to Jo Valentine, former program coordinator of the CDC's Syphilis Elimination Effort. As cases rose, the CDC modified its goals in 2006 from 0.4 primary and secondary syphilis cases per 100,000 in population to 2.2 cases per 100,000. By 2013, as elimination seemed less and less viable, the CDC changed its focus to ending congenital syphilis only.Since then, funding has remained anemic. From 2015 to 2020, the CDC's budget for preventing sexually transmitted infections grew by 2.2%. Taking inflation into account, that's a 7.4% reduction in purchasing power. In the same period, cases of syphilis, gonorrhea, and chlamydia - the three STDs that have federally funded control programs - increased by nearly 30%."We have a long history of nearly eradicating something, then changing our attention, and seeing a resurgence in numbers," David Harvey, executive director of the National Coalition of STD Directors, said. "We have more congenital syphilis cases today in America than we ever had pediatric AIDS at the height of the AIDS epidemic. It's heartbreaking."Adriane Casalotti, chief of government and public affairs at the National Association of County and City Health Officials, warns that the US should not be surprised to see case counts continue to climb."The bugs don't go away," she said. "They're just waiting for the next opportunity, when you're not paying attention."Syphilis has fewer poster children than HIV or cancerYang waited until the end of the day, then called the clinic to see if Angelica had gone for her shot. She had not. Yang would have to block off another half day to visit Huron again, but she had three dozen other cases to deal with.States in the South and West have seen the highest syphilis rates in recent years. In 2017, 64 babies in Fresno County were born with syphilis at a rate of 440 babies per 100,000 live births - about 19 times the national rate. While the county had managed to lower case counts in the two years that followed, the pandemic threatened to unravel that progress, forcing STD staffers to do COVID-19 contact tracing, pausing field visits to find infected people, and scaring patients from seeking care. Yang's colleague handled three cases of stillbirth in 2020; in each, the woman was never diagnosed with syphilis because she feared catching the coronavirus and skipped prenatal care.Yang, whose caseload peaked at 70 during a COVID-19 surge, knew she would not be able handle them all as thoroughly as she'd like to."When I was being mentored by another investigator, he said: 'You're not a superhero. You can't save everybody,'" she said.She prioritizes men who have sex with men, because there's a higher prevalence of syphilis in that population, and pregnant people, because of the horrific consequences for babies.The job of a disease intervention specialist isn't for everyone: It means meeting patients whenever and wherever they are available - in the mop closet of a bus station, in a quiet parking lot - to inform them about the disease, to extract names of sex partners, and to encourage treatment. Patients are often reluctant to talk. They can get belligerent, upset that "the government" has their personal information, or shattered at the thought that a partner is likely cheating on them. Salaries typically start in the low $40,000s.Jena Adams, Yang's supervisor, has eight investigators working on HIV and syphilis. In the middle of 2020, she lost two and replaced them only recently."It's been exhausting," Adams said.She has only one specialist who is trained to take blood samples in the field, crucial for guaranteeing that the partners of those who test positive for syphilis also get tested. Adams wants to get phlebotomy training for the rest of her staff, but it's $2,000 per person. The department also doesn't have anyone who can administer penicillin injections in the field; that would have been key when Yang met Angelica. For a while, a nurse who worked in the tuberculosis program would ride along to give penicillin shots on a volunteer basis. Then he, too, left the health department.Much of the resources in public health trickle down from the CDC, which distributes money to states, which then parcel it out to counties. The CDC gets its budget from Congress, which tells the agency, by line item, exactly how much money it can spend to fight a disease or virus, in an uncommonly specific manner not seen in many other agencies. The decisions are often politically driven and can be detached from actual health needs.When the House and Senate appropriations committees meet to decide how much the CDC will get for each line item, they are barraged by lobbyists for individual disease interests. Stephanie Arnold Pang, senior director of policy and government relations at the National Coalition of STD Directors, can pick out the groups by sight: breast cancer wears pink, Alzheimer's goes in purple, multiple sclerosis comes in orange, HIV in red. STD prevention advocates, like herself, don a green ribbon, but they're far outnumbered.And unlike diseases that might already be familiar to lawmakers, or have patient and family spokespeople who can tell their own powerful stories, syphilis doesn't have many willing poster children. Breast Cancer survivors hold up a check for the amount raised at The Congressional Womens Softball Game at Watkins Recreation Center in Capitol Hill on June 20, 2018. Sarah Silbiger/CQ Roll Call "Congressmen don't wake up one day and say, 'Oh hey, there's congenital syphilis in my jurisdiction.' You have to raise awareness," Arnold Pang said. It can be hard jockeying for a meeting. "Some offices might say, 'I don't have time for you because we've just seen HIV.' ... Sometimes, it feels like you're talking into a void."The consequences of the political nature of public-health funding have become more obvious during the coronavirus pandemic. The 2014 Ebola epidemic was seen as a "global wakeup call" that the world wasn't prepared for a major pandemic, yet in 2018, the CDC scaled back its epidemic prevention work as money ran out."If you've got to choose between Alzheimer's research and stopping an outbreak that may not happen? Stopping an outbreak that might not happen doesn't do well," Frieden, the former CDC director, said. "The CDC needs to have more money and more flexible money. Otherwise, we're going to be in this situation long term."In May 2021, President Joe Biden's administration announced it would set aside $7.4 billion over the next five years to hire and train public health workers, including $1.1 billion for more disease intervention specialists like Yang. Public health officials are thrilled to have the chance to expand their workforce, but some worry the time horizon may be too short."We've seen this movie before, right?" Frieden said. "Everyone gets concerned when there's an outbreak, and when that outbreak stops, the headlines stop, and an economic downturn happens, the budget gets cut."Fresno's STD clinic was shuttered in 2010 amid the Great Recession. Many others have vanished since the passage of the Affordable Care Act.Health leaders thought "by magically beefing up the primary care system, that we would do a better job of catching STIs and treating them," Harvey, the executive director of the National Coalition of STD Directors, said.That hasn't worked out; people want access to anonymous services, and primary care doctors often don't have STDs top of mind. The coalition is lobbying Congress for funding to support STD clinical services, proposing a three-year demonstration project funded at $600 million.It's one of Adams' dreams to see Fresno's STD clinic restored as it was."You could come in for an HIV test and get other STDs checked," she said. "And if a patient is positive, you can give a first injection on the spot."'I've seen people's families ripped apart and I've seen beautiful babies die'On August 12, Yang set out for Huron again, speeding past groves of almond trees and fields of grapes in the department's white Chevy Cruze. She brought along a colleague, Jorge Sevilla, who had recently transferred to the STD program from COVID-19 contact tracing. Yang was anxious to find Angelica again."She's probably in her second trimester now," she said.They found her outside of a pale yellow house a few blocks from the homeless encampment; the owner was letting her stay in a shed tucked in the corner of the dirt yard. This time, it was evident that she was pregnant. Yang noted that Angelica was wearing a wig; hair loss is a symptom of syphilis."Do you remember me?" Yang asked.Angelica nodded. She didn't seem surprised to see Yang again. (I came along, and Sevilla explained who I was and that I was writing about syphilis and the people affected by it. Angelica signed a release for me to report about her case, and she said she had no problem with me writing about her or even using her full name. ProPublica chose to only print her first name.)"How are you doing? How's the baby?""Bien.""So the last time we talked, we were going to have you go to United Healthcare Center to get treatment. Have you gone since?"Angelica shook her head."We brought some gift cards..." Sevilla started in Spanish. The department uses them as incentives for completing injections. But Angelica was already shaking her head. The nearest Walmart was the next town over.Yang turned to her partner. "Tell her: So the reason why we're coming out here again is because we really need her to go in for treatment. [...] We really are concerned for the baby's health especially since she's had the infection for quite a while."Angelica listened while Sevilla interpreted, her eyes on the ground. Then she looked up. "Orita?" she asked. Right now?"I'll walk with you," Yang offered. Angelica shook her head."She said she wants to shower first before she goes over there," Sevilla said.Yang made a face. "She said that to me last time." Yang offered to wait, but Angelica didn't want the health officers to linger by the house. She said she would meet them by the clinic in 15 minutes.Yang was reluctant to let her go but again had no other option. She and Sevilla drove to the clinic, then stood on the corner of the parking lot, staring down the road.Talk to the pediatricians, obstetricians, and families on the front lines of the congenital syphilis surge and it becomes clear why Yang and others are trying so desperately to prevent cases. J.B. Cantey, associate professor in pediatrics at UT Health San Antonio, remembers a baby girl born at 25 weeks gestation who weighed a pound and a half. Syphilis had spread through her bones and lungs. She spent five months in the neonatal intensive care unit, breathing through a ventilator, and was still eating through a tube when she was discharged.Then, there are the miscarriages, the stillbirths, and the inconsolable parents. Irene Stafford, an associate professor and maternal-fetal medicine specialist at UT Health in Houston, cannot forget a patient who came in at 36 weeks for a routine checkup, pregnant with her first child. Stafford realized that there was no heartbeat."She could see on my face that something was really wrong," Stafford recalled. She had to let the patient know that syphilis had killed her baby."She was hysterical, just bawling," Stafford said. "I've seen people's families ripped apart and I've seen beautiful babies die." Fewer than 10% of patients who experience a stillbirth are tested for syphilis, suggesting that cases are underdiagnosed.A Texas grandmother named Solidad Odunuga offers a glimpse into what the future could hold for Angelica's mother, who may wind up raising her baby.In February of last year, Odunuga got a call from the Lyndon B. Johnson Hospital in Houston. A nurse told her that her daughter was about to give birth and that child protective services had been called. Odunuga had lost contact with her daughter, who struggled with homelessness and substance abuse. She arrived in time to see her grandson delivered, premature at 30 weeks old, weighing 2.7 pounds. He tested positive for syphilis.When a child protective worker asked Odunuga to take custody of the infant, she felt a wave of dread."I was in denial," she recalled. "I did not plan to be a mom again." The baby's medical problems were daunting: "Global developmental delays [...] concerns for visual impairments [...] high risk of cerebral palsy," read a note from the doctor at the time.Still, Odunuga visited her grandson every day for three months, driving to the NICU from her job at the University of Houston. "I'd put him in my shirt to keep him warm and hold him there." She fell in love. She named him Emmanuel.Once Emmanuel was discharged, Odunuga realized she had no choice but to quit her job. While Medicaid covered the costs of Emmanuel's treatment, it was on her to care for him. From infancy, Emmanuel's life has been a whirlwind of constant therapy. Today, at 20 months old, Odunuga brings him to physical, occupational, speech, and developmental therapy, each a different appointment on a different day of the week.Emmanuel has thrived beyond what his doctors predicted, toddling so fast that Odunuga can't look away for a minute and beaming as he waves his favorite toy phone. Yet he still suffers from gagging issues, which means Odunuga can't feed him any solid foods. Liquid gets into his lungs when he aspirates; it has led to pneumonia three times. Emmanuel has a special stroller that helps keep his head in a position that won't aggravate his persistent reflux, but Odunuga said she still has to pull over on the side of the road sometimes when she hears him projectile vomiting from the backseat.The days are endless. Once she puts Emmanuel to bed, Odunuga starts planning the next day's appointments."I've had to cry alone, scream out alone," she said. "Sometimes I wake up and think, 'Is this real?' And then I hear him in the next room."There's no vaccine for syphilis A health worker tests a migrant from Haiti for HIV and syphilis to in Ciudad Acuna, Mexico, on September 25, 2021. Daniel Becerril/Reuters Putting aside the challenge of eliminating syphilis entirely, everyone agrees it's both doable and necessary to prevent newborn cases."There was a crisis in perinatal HIV almost 30 years ago and people stood up and said this is not OK - it's not acceptable for babies to be born in that condition. [...We] brought it down from 1,700 babies born each year with perinatal HIV to less than 40 per year today," Virginia Bowen, an epidemiologist at the CDC, said. "Now here we are with a slightly different condition. We can also stand up and say, 'This is not acceptable.'" Belarus, Bermuda, Cuba, Malaysia, Thailand, and Sri Lanka are among countries recognized by the World Health Organization for eliminating congenital syphilis.Success starts with filling gaps across the health care system.For almost a century, public health experts have advocated for testing pregnant patients more than once for syphilis in order to catch the infection. But policies nationwide still don't reflect this best practice. Six states have no prenatal screening requirement at all. Even in states that require three tests, public-health officials say that many physicians aren't aware of the requirements. Stafford, the maternal-fetal medicine specialist in Houston, says she's tired of hearing her own peers in medicine tell her, "Oh, syphilis is a problem?"It costs public health departments less than 25 cents a dose to buy penicillin, but for a private practice, it's more than $1,000, according to Park of the University of California San Francisco."There's no incentive for a private physician to stock a dose that could expire before it's used, so they often don't have it," she said. "So a woman comes in, they say, 'We'll send you to the emergency department or health department to get it,' then [the patients] don't show up."A vaccine would be invaluable for preventing spread among people at high risk for reinfection. But there is none. Scientists only recently figured out how to grow the bacteria in the lab, prompting grants from the National Institutes of Health to fund research into a vaccine. Justin Radolf, a researcher at the University of Connecticut School of Medicine, said he hopes his team will have a vaccine candidate by the end of its five-year grant. But it'll likely take years more to find a manufacturer and run human trials.Public-health agencies also need to recognize that many of the hurdles to getting pregnant people treated involve access to care, economic stability, safe housing, and transportation. In Fresno, Adams has been working on ways her department can collaborate with mental health services. Recently, one of her disease intervention specialists managed to get a pregnant woman treated with penicillin shots and, at the patient's request, connected her with an addiction treatment center.Gaining a patient's cooperation means seeing them as complex humans instead of just a case to solve."There may be past traumas with the healthcare system," Cynthia Deverson, project manager of the Houston Fetal Infant Morbidity Review, said. "There's the fear of being discovered if she's doing something illegal to survive. [...] She may need to be in a certain place at a certain time so she can get something to eat, or maybe it's the only time of the day that's safe for her to sleep. They're not going to tell you that. Yes, they understand there's a problem, but it's not an immediate threat, maybe they don't feel bad yet, so obviously this is not urgent.""What helps to gain trust is consistency," she added. "Literally, it's seeing that [disease specialist] constantly, daily. [...] The woman can see that you're not going to harm her, you're saying, 'I'm here at this time if you need me.'"Yang stood outside the clinic, waiting for Angelica to show up, baking in the 90-degree heat. Her feelings ranged from irritation - Why didn't she just go? I'd have more energy for other cases - to an appreciation for the parts of Angelica's story that she didn't know - She's in survival mode. I need to be more patient.Fifteen minutes ticked by, then 20."OK," Yang announced. "We're going back."She asked Sevilla if he would be OK if they drove Angelica to the clinic; they technically weren't supposed to because of coronavirus precautions, but Yang wasn't sure she could convince Angelica to walk. Sevilla gave her the thumbs up.When they pulled up, they saw Angelica sitting in the backyard, chatting with a friend. She now wore a fresh T-shirt and had shoes on her feet. Angelica sat silently in the back seat as Yang drove to the clinic. A few minutes later, they pulled up to the parking lot.Finally, Yang thought. We got her here.The clinic was packed with people waiting for COVID-19 tests and vaccinations. A worker there had previously told Yang that a walk-in would be fine, but a receptionist now said they were too busy to treat Angelica. She would have to return.Yang felt a surge of frustration, sensing that her hard-fought opportunity was slipping away. She tried to talk to the nurse supervisor, but he wasn't available. She tried to leave the gift cards at the office to reward Angelica if she came, but the receptionist said she couldn't hold them. While Yang negotiated, Sevilla sat with Angelica in the car, waiting.Finally, Yang accepted this was yet another thing she couldn't control.She drove Angelica back to the yellow house. As they arrived, she tried once more to impress on her just how important it was to get treated, asking Sevilla to interpret. "We don't want it to get any more serious, because she can go blind, she could go deaf, she could lose her baby."Angelica already had the door halfway open."So on a scale from one to 10, how important is this to get treated?" Yang asked."Ten," Angelica said. Yang reminded her of the appointment that afternoon. Then Angelica stepped out and returned to the dusty yard.Yang lingered for a moment, watching Angelica go. Then she turned the car back onto the highway and set off toward Fresno, knowing, already, that she'd be back.Postscript: A reporter visited Huron twice more in the months that followed, including once independently to try to interview Angelica, but she wasn't in town. Yang has visited Huron twice more as well - six times in total thus far. In October, a couple of men at the yellow house said Angelica was still in town, still pregnant. Yang and Sevilla spent an hour driving around, talking to residents, hoping to catch Angelica. But she was nowhere to be found.Read the original article on Business Insider.....»»

Category: personnelSource: nytNov 2nd, 2021

Hawaiian Airlines diverted 2 flights in less than 12 hours after one passenger assaulted a flight attendant and another refused to wear a mask

Two Hawaiian Airlines flights from Honolulu were diverted Thursday after a passenger hit a flight attendant "unprovoked" and another refused to mask. Mehmet Ali Ozcan/Anadolu Agency/Getty Images Two Hawaiian Airlines flights were diverted Thursday over disturbances from unruly passengers. One of the flyers assaulted a flight attendant walking down the aisle in an "unprovoked incident." The unruly passenger on the other flight refused to wear a mask. See more stories on Insider's business page. Hawaiian Airlines diverted two flights in under 12 hours this week after unruly passengers onboard caused disturbances.On Thursday morning, a flight from Honolulu to Hilo was forced to return to the airport after "a passenger assaulted one of our flight attendants, who was walking the aisle, in an unprovoked incident," a company spokesperson told The Honolulu Star-Advertiser.The passenger, a 32-year-old man, was arrested for third-degree assault when he deplaned, a spokesperson for Hawaii's Department of Public Safety told the Associated Press. The FBI is investigating the incident, an agency spokesperson told the AP. The flight attendant, meanwhile, was "evaluated and released from work to rest," Hawaiian Airlines told the Star-Advertiser.Later on Thursday, another Hawaiian Airlines flight ran into trouble. On a flight from Honolulu to Seattle, a passenger refused to wear a mask and "caused a disturbance," a company spokesperson told the Star-Advertiser. Flight attendants and an off-duty pilot de-escalated the situation, but the flight was diverted out of an abundance of caution. No one was injured.The incidents come amid a spike in passenger disturbances onboard commercial flights. The FAA said this week that it has received more than 4,000 reports of unruly passengers so far this year, but only one has resulted in a person being criminally charged. That incident involved a Southwest Airlines passenger who was seen punching a flight attendant in the face in a viral video. Many flight attendants are dealing with burnout and adverse effects on their mental health due to the surge in passenger violence, as Insider's Allana Akhtar reported.Delta Airlines recently said it had banned 1,600 passengers and called on others in the industry to share their "no-fly" passenger lists as well.Hawaiian Airlines did not respond to a request for comment. Read the original article on Business Insider.....»»

Category: worldSource: nytSep 24th, 2021

How Amazon plans to expand into mental health services with on-demand therapists

Amazon plans to add mental health support to its primary-care service, Hulu and Disney+ are about to get more expensive, and Musk teased a potential Twitter competitor. Insider has learned Amazon is planning to add mental health services to its portfolio — so one day you may not only have an Amazon robot cleaning your house, an Amazon doctor providing care, and an Amazon store to pick out your clothes, but you could also have an Amazon therapist.This post first appeared in 10 Things in Tech, a newsletter by Insider that brings you all the latest tech news & scoops — delivered daily to your inbox. Sign up here. Download Insider's app here.Amazon Care's app.Amazon Care1. Amazon plans to add mental health support to its primary-care service. Amazon's primary-care service, Amazon Care, plans to add behavioral health support to its growing list of medical offerings, and is planning to partner with mental health care provider Ginger.The service, which hasn't launched yet, will provide Amazon Care users on-demand access to mental health experts, such as licensed therapists or psychiatrists.The move would mark the latest expansion of Amazon's incipient primary-care business, which offers on-demand virtual care through an app, connecting people with physicians for primary care services. Amazon has been doubling down on its healthcare business. Just last month, the company announced plans to acquire One Medical for $3.9 billion. Inside Amazon's push for mental health support.In other news:In this photo illustration, a hand holding a TV remote control in front of the Disney Plus logo on a TV screen.Rafael Henrique/SOPA Images/LightRocket via Getty Images2. Hulu and Disney+ are about to get more expensive. The cost of an ad-free Disney+ subscription is increasing by 38% to $10.99. Meanwhile, a Hulu subscription without ads will increase $2 per month. Here's how much each plan is increasing, and when the changes go into effect.3. A leaked email shows Nvidia's CEO reassuring employees that layoffs aren't coming. The email, which came as the company missed its revenue targets, also said that Nvidia employees were given a raise "to take care of your families." What we learned from the email.4. Elon Musk teased his website "X.com" as a potential Twitter competitor. Musk, who bought the domain name in 2017 from PayPal as it had "sentimental value," is now hinting that it could serve as a direct competitor to Twitter. What we know about X.com.5. Snap employees are bracing for layoffs. A recent Q&A call with Snap's head of engineering left some workers feeling like layoffs at the company are not a matter of if, but when. See what Snap employees are saying.6. Jeff Bezos, Bill Gates, and other billionaires are backing an exploration for rare minerals buried beneath Greenland's ice. The billionaires are helping fund KoBold Metals, a startup that's searching for minerals and metals that can be used to build electric cars and renewable batteries. Get the full rundown here.7. Microsoft is cutting hundreds of contractors amid layoffs and a hiring freeze. This week, the workers were told their contracts will end on Friday, and that they won't receive severance. Everything contract workers told us about the layoffs.8. Most electric cars won't qualify for Democrats' new $7,500 tax credit. The Inflation Reduction Act includes a renewed tax credit for electric-car buyers — but the new program has restrictions that would exclude most current electric models. Here's a look at why.Odds and ends:Susan Walsh/AP; Guy Fleury/AP9. Jeff Bezos' megayacht is close to being finished. Video shows the massive — and controversial — megayacht appears to be fully assembled. See a video of the yacht up close.10. WhatsApp will finally let users quietly leave group chats. As part of a rollout of new privacy features, the company is implementing an update that lets users leave group chats without notifying others. Here's what else the update offers.What we're watching today:DEF CON conference for computer hackers starts in Las Vegas.Wikimania, an annual gathering bringing together Wikipedia volunteers, starts today. It's Steve Wozniak's birthday.Keep updated with the latest tech news throughout your day by checking out The Refresh from Insider, a dynamic audio news brief from the Insider newsroom. Listen here.Curated by Jordan Parker Erb in New York. (Feedback or tips? Email jerb@insider.com or tweet @jordanparkererb.) Edited by Hallam Bullock (tweet @hallam_bullock) in London.Read the original article on Business Insider.....»»

Category: smallbizSource: nyt56 min. ago

Amazon plans to expand into mental health services

Amazon plans to add mental health support to its primary-care service, Hulu and Disney+ are about to get more expensive, and Musk teased a potential Twitter competitor. The Amazon-ification of our daily lives continues. The tech giant has already been on something of a shopping spree this summer, announcing its intent to scoop up Roomba-maker iRobot and One Medical, a chain of physician offices.Now, Insider has learned Amazon is also planning to add mental health services to its portfolio — so one day you may not only have an Amazon robot cleaning your house, an Amazon doctor providing care, and an Amazon store to pick out your clothes, but you could also have an Amazon therapist.Jordan Parker Erb here, just thinking about where the company could head next.If this was forwarded to you, sign up here. Download Insider's app here.Amazon Care's app.Amazon Care1. Amazon plans to add mental health support to its primary-care service. Amazon's primary-care service, Amazon Care, plans to add behavioral health support to its growing list of medical offerings, and is planning to partner with mental health care provider Ginger.The service, which hasn't launched yet, will provide Amazon Care users on-demand access to mental health experts, such as licensed therapists or psychiatrists.The move would mark the latest expansion of Amazon's incipient primary-care business, which offers on-demand virtual care through an app, connecting people with physicians for primary care services. Amazon has been doubling down on its healthcare business. Just last month, the company announced plans to acquire One Medical for $3.9 billion. Inside Amazon's push for mental health support.In other news:In this photo illustration, a hand holding a TV remote control in front of the Disney Plus logo on a TV screen.Rafael Henrique/SOPA Images/LightRocket via Getty Images2. Hulu and Disney+ are about to get more expensive. The cost of an ad-free Disney+ subscription is increasing by 38% to $10.99. Meanwhile, a Hulu subscription without ads will increase $2 per month. Here's how much each plan is increasing, and when the changes go into effect.3. A leaked email shows Nvidia's CEO reassuring employees that layoffs aren't coming. The email, which came as the company missed its revenue targets, also said that Nvidia employees were given a raise "to take care of your families." What we learned from the email.4. Elon Musk teased his website "X.com" as a potential Twitter competitor. Musk, who bought the domain name in 2017 from PayPal as it had "sentimental value," is now hinting that it could serve as a direct competitor to Twitter. What we know about X.com.5. Snap employees are bracing for layoffs. A recent Q&A call with Snap's head of engineering left some workers feeling like layoffs at the company are not a matter of if, but when. See what Snap employees are saying.6. Jeff Bezos, Bill Gates, and other billionaires are backing an exploration for rare minerals buried beneath Greenland's ice. The billionaires are helping fund KoBold Metals, a startup that's searching for minerals and metals that can be used to build electric cars and renewable batteries. Get the full rundown here.7. Microsoft is cutting hundreds of contractors amid layoffs and a hiring freeze. This week, the workers were told their contracts will end on Friday, and that they won't receive severance. Everything contract workers told us about the layoffs.8. Most electric cars won't qualify for Democrats' new $7,500 tax credit. The Inflation Reduction Act includes a renewed tax credit for electric-car buyers — but the new program has restrictions that would exclude most current electric models. Here's a look at why.Odds and ends:Susan Walsh/AP; Guy Fleury/AP9. Jeff Bezos' megayacht is close to being finished. Video shows the massive — and controversial — megayacht appears to be fully assembled. See a video of the yacht up close.10. WhatsApp will finally let users quietly leave group chats. As part of a rollout of new privacy features, the company is implementing an update that lets users leave group chats without notifying others. Here's what else the update offers.What we're watching today:DEF CON conference for computer hackers starts in Las Vegas.Wikimania, an annual gathering bringing together Wikipedia volunteers, starts today. It's Steve Wozniak's birthday.Keep updated with the latest tech news throughout your day by checking out The Refresh from Insider, a dynamic audio news brief from the Insider newsroom. Listen here.Curated by Jordan Parker Erb in New York. (Feedback or tips? Email jerb@insider.com or tweet @jordanparkererb.) Edited by Hallam Bullock (tweet @hallam_bullock) in London.Read the original article on Business Insider.....»»

Category: smallbizSource: nyt3 hr. 40 min. ago

Democratic Bill Passes Senate, With Changes

Not yet law but now much closer to receiving President Biden’s signature, the Democratic “Inflation Reduction Act” survived a careful balancing act between centrists and progressive members of the caucus, along with virulent opposition from Republicans and is likely headed for a vote in the House this week. Focused mostly on health care and climate… The post Democratic Bill Passes Senate, With Changes appeared first on RISMedia......»»

Category: realestateSource: rismedia16 hr. 32 min. ago

Semiconductor Stock Plunge: Buy, Sell or Hold?

This has been a bad week for semiconductor stocks so far, with NVDA and MU warning of significant demand destruction. This week has been a really bad one for semiconductor stocks, as first NVIDIA NVDA and then Micron MU announced that they were cutting their outlooks.NVIDIA put down its miss versus projections (and it was a huge 17.3% miss) to softness in the gaming business, which it said was because of lower sales at channel partners affected by macroeconomic concerns. Worse, CEO Jenseng Huang warned: “As we expect the macroeconomic conditions affecting sell-through to continue, we took actions with our Gaming partners to adjust channel prices and inventory.”What that boils down to then is slowing demand for discretionary items, as well as devices (PCs, smartphones, gaming devices, etc.). That could be first, because some of that spend has been diverted to services and the “opening up” economy, especially because people have bought a lot in the last 1-2 years and don’t need more of the devices right now. And second, because there really is a problem called inflation that despite all the stimulus cash, is beginning to hurt some customers.This softening in demand could be a signal that the economy is going where the Fed intended. Only, as far as these fabless semiconductor companies are concerned, they are seeing increased costs because of supply chain issues and the Taiwan-China-US tension isn’t helping things at all. If anything, there’s a lot of concern about the future of chip supply given Taiwan’s leading position there. Taiwan Semiconductor Company TSM is seeing more demand than it can fill, and being a manufacturer, is in a position to keep raising prices. It’s customers, like NVIDIA are getting squeezed (seen from the more than 20 bps miss on the gross margin).    It is not too much of a stretch to think that the softness in crypto is also affecting NVIDIA, as it is Advanced Micro Devices AMD. And like AMD, NVIDIA is saying that supply chain issues are leading to softer-than-expected growth in the data center, which is nevertheless still growing very strongly.Micron followed soon after NVIDIA with an announcement of its own that macroeconomic conditions had materially deteriorated, leading to softening demand for its DRAM and NAND memory chips since its call on Jun 30. Additionally, it expects the adverse conditions to continue, posing significant challenges in the next two quarters. Capex is also being cut as a result.Expectedly, the entire segment is in the red since then, with chipmakers including AMD, NVDA, QCOM, MU, TSM, AMAT, INTC all selling off.A quick dip into Intel’s INTC 14.5% sales miss in the last-reported quarter shows double-digit revenue misses across all segments except Network and Edge. Intel continues to bleed market share in the data center, accounting for the year-over-year decline and 24% miss versus analyst estimates in that segment. Both desktop and notebook missed estimates because of the above-mentioned factors, although the accelerated computing and graphics product line surprised positively. All except Mobileye and All Other segments missed analysts’ profit estimates. Analysts expect both revenue and profits in the current quarter to come down slightly (on a year-over-year basis) in its most significant Client and Data Center segments.RecommendationsAs is probably obvious from the above discussion, the semiconductor segment is not a good place to put your money in right now. In case of companies like NVIDIA, Qualcomm, Micron and AMD, you will likely find a better entry point because things look to be headed down before they move up again. Intel is in a long-term bind and is not recommended any time in the near future. Therefore, selling Intel, Micron, AMD and NVDA instead sounds like a good plan.There are a couple of stocks that stand out however.TSM is one that benefits by virtue of being a low-cost manufacturer and despite all fabless players looking desperately to diversify their supply chains, these things take time. So in the meantime, TSM is the only hope for many, especially given its prowess at the leading edge.Another stock that is usually a good defensive play is Texas Instruments TXN. The fact that it has its own fabs and relatively low exposure to Asian manufacturing is an added advantage.One-Month Price PerformanceImage Source: Zacks Investment Research Profiting from the Metaverse, The 3rd Internet Boom (Free Report): Get Zacks' special report revealing top profit plays for the internet's next evolution. Early investors still have time to get in near the "ground floor" of this $30 trillion opportunity. You'll discover 5 surprising stocks to help you cash in.Download the report FREE today >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intel Corporation (INTC): Free Stock Analysis Report Texas Instruments Incorporated (TXN): Free Stock Analysis Report Micron Technology, Inc. (MU): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report Taiwan Semiconductor Manufacturing Company Ltd. (TSM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacks16 hr. 33 min. ago

What Makes Evolent Health (EVH) a Strong Momentum Stock: Buy Now?

Does Evolent Health (EVH) have what it takes to be a top stock pick for momentum investors? Let's find out. Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.Below, we take a look at Evolent Health (EVH), a company that currently holds a Momentum Style Score of A. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Evolent Health currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.You can see the current list of Zacks #1 Rank Stocks here >>>Set to Beat the Market?Let's discuss some of the components of the Momentum Style Score for EVH that show why this health care software and consulting services provider shows promise as a solid momentum pick.A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.For EVH, shares are up 5.15% over the past week while the Zacks Internet - Software industry is up 5.46% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 19.68% compares favorably with the industry's 10.3% performance as well.Considering longer term price metrics, like performance over the last three months or year, can be advantageous as well. Over the past quarter, shares of Evolent Health have risen 16.97%, and are up 44.24% in the last year. On the other hand, the S&P 500 has only moved 3.71% and -5.55%, respectively.Investors should also pay attention to EVH's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. EVH is currently averaging 975,598 shares for the last 20 days.Earnings OutlookThe Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with EVH.Over the past two months, 3 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost EVH's consensus estimate, increasing from $0.24 to $0.28 in the past 60 days. Looking at the next fiscal year, 1 estimate has moved upwards while there have been 2 downward revisions in the same time period.Bottom LineGiven these factors, it shouldn't be surprising that EVH is a #2 (Buy) stock and boasts a Momentum Score of A. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep Evolent Health on your short list. Profiting from the Metaverse, The 3rd Internet Boom (Free Report): Get Zacks' special report revealing top profit plays for the internet's next evolution. Early investors still have time to get in near the "ground floor" of this $30 trillion opportunity. You'll discover 5 surprising stocks to help you cash in.Download the report FREE today >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Evolent Health, Inc (EVH): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Category: topSource: zacks16 hr. 33 min. ago

Citi warns these key tech stocks are facing their worst downturn since the dotcom bust - and that"s a red flag for the global economy

The Philadelphia Semiconductor Index has plunged 27% in 2022, and there's likely further pain ahead for chip makers like Nvidia and Micron. Citi has warned of a downturn for semiconductor stocks - which have already plunged 27% year-to-date.Michael Buholzer/Reuters Citi has warned struggling semiconductor stocks are set to fall further as the global economy worsens. The Philadelphia Semiconductor Index has lost 27% this year, while Nvidia and Micron warned on revenue outlook. "We expect every company and every end-market to experience a correction," Citi analyst Christopher Danely said. Semiconductor stocks are headed for a prolonged downturn as recession risks pile up, Citigroup has warned.The bank's gloomy forecast comes after Nvidia and Micron Technology, key names in the sector, saw their share prices tumble this week after they warned about the outlook for revenue.Semiconductor companies are seen as an important bellwether for the health of the global economy, because the chips they manufacture are key components in cars, computers, and mobile phones.Stocks in the sector have struggled in 2022, with the Philadelphia Semiconductor Index (SOX) plummeting over 27% year-to-date — and Citi doesn't expect the sell-off to end any time soon."We continue to believe we are entering the worst semiconductor downturn in at least a decade, and possibly since 2001," analyst Christopher Danely said in a recent research note. "We expect every company in our coverage universe and every end-market to experience a correction."Citi believes upcoming data on PC and mobile phones will show a further weakening, and that updates on datacenters, autos and industrial chip use will be similarly negative.A comparable downturn to that in 2001 would see the SOX lose half of its current value. The index crashed by 79.6% between March 2000 and September that year, as the dotcom bubble burst.Nvidia has fallen 10.1% to below $171 a share after the chip maker warned Monday of a revenue slowdown and a softening in gaming demand. Meanwhile, Micron's stock has slipped 8.9% since it reported a decline in demand for its chips and warned of a challenging market environment.Micron chief executive Sanjay Mehrotra said that slowing economic growth would weaken chip demand in "parts of the market including data centers, industrial and automotive," speaking in an interview with Bloomberg TV earlier this week.Mehrotra's warning reflects the rising likelihood of a recession and means that there will likely be further pain ahead for chip makers, according to Danely."Micron is the first company to mention weakness in the automotive and industrial end markets, and we would note Micron has been a leading indicator in the downturn all year," Danely said.Chip sales growth has now decelerated six months in a row - and there's a strong correlation between that data and the performance of the global economy, according to the Semiconductor Industry Association.Chips' crucial role in the manufacturing of technology including cars, computers, and mobile phones means they offer significant insight into global aggregate demand.Read more: Buy these 10 recession-proof stocks that look cheap given their track record in weathering economic downturns, according to MorningstarRead the original article on Business Insider.....»»

Category: dealsSource: nytAug 10th, 2022

Previewing The "Historic" July CPI Report, And Why A Miss Will Make Powell"s Life Extremely Hard

Previewing The "Historic" July CPI Report, And Why A Miss Will Make Powell's Life Extremely Hard As Bloomberg's Sebastian Boyd writes, it’s hard to overstate the importance of Wednesday’s US inflation report to a market that’s split between two different views of the economy, and the Fed’s plans for dealing with it. The report is critical because - among other things - two weeks ago, at his July 27 press conference, Powell said the Fed would slow the pace of hikes at some point... but he also made clear that the central bank thinks the labor market remains strong and that is offsetting the slowdown in demand. Friday’s nonfarms payrolls data bore that out in a stunning way, with the US economy creating far more jobs than any of the 71 economists in Bloomberg’s survey expected (granted, the Household survey painted an entirely different picture but we'll cross that bridge in time). For all intents and purposes, the market saw the number as super hawkish, and while Fed funds were pricing in a 36% chance of a 75-bp September hike before payrolls, they’re now looking at a 74% probability. There were more pre-CPI signals in the bond market on Tuesday, when the stellar three-year Treasury bond auction proved that if there are any jitters about another big upside surprise, the bond market doesn't see it. As Bloomberg's Alyce Andres pointed out, the short end is acutely sensitive to expectations for both rates and inflation, so were traders worried about a surprise on Wednesday, the sale could have struggled. In the event, the auction went fine, and some traders were seen setting themselves up for a downside inflation surprise. Finally, as we noted earlier, the curve bear flattened even more - as it has been doing since the nonfarm payrolls data on Friday - and the 2s10s curve is set a new multi-decade low. That suggests that investors are bracing for more hawkishness from the Fed, as inflation remains stubborn and the labor-market tight, "and that the the market thinks the space for then avoiding a recession is getting narrower and narrower." So what does the market expect? Consensus expects that headline CPI will rise just 0.2% in July, far below the previous month's 1.3% increase, largely on the back of a sharp drop in energy prices. Core CPI is expected to rise by a brisker 0.5%, still down from last month's 0.7%. The YoY headline is expected to print 8.7%, also down from the 9.1% last month, while Core CPI will rise 6.1% compared to a year ago, an increase vs the 5.9% Y/Y rise in June. Goldman economists are looking for a slightly higher headline YoY CPI of +8.83% and an in-line Core print of +6.09% (vs +6.1% consensus and +5.9% prior). On a monthly basis, Goldman expects a 0.48% increase in July core CPI, a hair below consensus expectations for a 0.5%. The bank also forecasts a 0.24% increase in headline CPI in July, a bit above consensus expectations for a 0.2% increase (and as noted above, corresponding to a 0.3% decline in the year-over-year rate to 8.83%). In its CPI preview note (available to pro subs along with a bunch of other pre-CPI reports) Goldman highlights three component-level trends for the July report. First, the bank expects shelter inflation to remain elevated as the official shelter index continues to catch up to the price levels implied by alternative web-based measures of rent inflation (something we were warning about over a year ago). Specifically, Goldman expects OER to increase by 0.6%, as the recent price increases for natural gas and other utilities which the BLS imputes and removes from OER likely lead it to increase by less than rent in July. Going forward, shelter inflation is expected to slow to a 0.4-0.5% monthly pace by year-end and peak at around 7% year-over-year later this year. Second, Goldman expects the energy component of the CPI to decline by 3.2%, reflecting a sharp drop in gasoline prices in July. Futures prices point to further declines ahead, suggesting that headline inflation will likely continue to moderate in the near term. Third, the decline in fuel prices has likely contributed to lower airfares, and the bank expects the airfares component to decline by 7% in this week’s report. Elsewhere in the report, Goldman expects continued increases in auto prices (new +1.0%, used +0.5%, parts +0.8%). Additionally, retailers have noted that they anticipate cutting prices in coming months in order to reduce inventory stocks from elevated levels, and apparel prices are expected to shrink by 0.8%. Looking ahead, Goldman expect monthly core CPI inflation to remain in the 0.4-0.5% range for the next couple months before edging down to 0.3-0.4% by December 2022. The bank forecasts year-over-year core CPI inflation of 6.1% in December 2022, 2.7% in December 2023, and 2.8% in December 2024, with the bank's forecast reflecting a negative swing in health insurance prices and a larger slowdown in goods than in services inflation next year. That said, even assuming sequential inflation growth slows to a trickle, the chart below from BofA shows how long it will take for inflation to normalize on an annual basis. In terms of the market reaction, Goldman's John Flood writes today that "a softer than expected reading (anything better than prior of 9.1%) likely “stops in” more buyers. I think the print will have to be quite HOT (headline well above prior reading of 9.1%) to apply any real pressure to the tape, because sellers are hard to come by. I think this dynamic essentially rings true for remainder of August and then we can reevaluate post labor day. As painful as it is any headline reading that falls btwn soft and very hot (really anything lower than 9.5%?) keeps current trend of choppy and higher going (as corporates and quants continue to methodically buy)." In other words, while a CPI miss is likely - especially at the headline level - and it will push risk assets even higher, this is the worst possible outcome for the Fed which will be left with only red-hot jobs as the only "real time data" preventing it from pivoting, and why the next time we get a big NFP miss, stocks will hit escape velocity. Tyler Durden Tue, 08/09/2022 - 21:49.....»»

Category: worldSource: nytAug 9th, 2022

5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings. It has been a better-than-expected earnings season for the drug and biotech sector. Most companies beat consensus EPS and revenue estimates. Though a few drug/biotech companies did lower their financial guidance, most of them either maintained or raised their guidance for the year. There are some smaller biotechs, which are yet to report in this last week of the earnings season.Per the Zacks classification, the pharma/biotech industry comes under the broader Medical sector, which comprises pharma/biotech as well as medical device companies.Per the Earnings Trends report, as of Jul 27, 25% of the Medical sector companies, constituting nearly 41.2% of the sector’s market capitalization, reported earnings. While 85.7% of the companies beat on earnings, 78.6% surpassed revenue estimates. Earnings increased 5.1% year over year, while revenues rose 10.7%.Overall, second-quarter earnings of the Medical sector are expected to rise 1.1%, while revenues are projected to increase 7.9%.Zeroing in on WinnersHere we have highlighted five biotech companies — Absci Corporation ABSI Axcella Health AXLA, Freeline Therapeutics Holdings FRLN, DICE Therapeutics DICE, Pliant Therapeutics PLRX — that are expected to deliver a beat in their upcoming quarterly results.Earnings ESP is our proprietary methodology for determining the stocks that have the best chance to deliver an earnings surprise. Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate.According to the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. The selection can be done with the help of the Zacks Stock Screener.Our research shows that for stocks with this combination, the chance of an earnings surprise is as high as 70%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.5 Drug/Biotech Stocks That Match the CriteriaAbsci Corporation This AI-powered synthetic biology company has an Earnings ESP of +1.59% and a Zacks Rank of 3. The Zacks Consensus Estimate for the second quarter is pegged at a loss of 32 cents per share. Absci is expected to release results later this month.Angion Biomedica missed estimates in three of the last four quarters while beating in one, with the average negative surprise being 15.20%Absci Corporation Price and EPS Surprise Absci Corporation price-eps-surprise | Absci Corporation QuoteYou can see the complete list of today’s Zacks #1 Rank stocks hereAxcella HealthA clinical-stage biotech, Axcella Health makes novel multifactorial interventions to support health and address dysregulated metabolism. Axcella Health has an Earnings ESP of +1.69% and a Zacks Rank of 3. The Zacks Consensus for the second quarter is pegged at a loss of 36 cents per share.Axcella Health beat estimates in one of the last four quarters while missing in two and delivering in-line results in one. The company’s four-quarter average negative earnings surprise is 4.79%. The company should release results this month.Axcella Health Inc. Price, Consensus and EPS Surprise Axcella Health Inc. price-consensus-eps-surprise-chart | Axcella Health Inc. QuoteFreeline Therapeutics This clinical-stage biotechnology company makes AAV-based gene therapy targeting the liver. Freeline Therapeutics has an Earnings ESP of +21.50% and a Zacks Rank of #2. The Zacks Consensus Estimate for the second quarter is pegged at a loss of 54 cents per share.Freeline Therapeutics missed estimates in three of the last four quarters while beating in one with the average negative earnings surprise being 11.72%.Freeline Therapeutics Holdings PLC Sponsored ADR Price, Consensus and EPS Surprise Freeline Therapeutics Holdings PLC Sponsored ADR price-consensus-eps-surprise-chart | Freeline Therapeutics Holdings PLC Sponsored ADR QuoteDICE Therapeutics This biotech makes novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DICE Therapeutics has an Earnings ESP of +0.90% and a Zacks Rank of 3. The Zacks Consensus Estimate for the second quarter is pegged at a loss of 56 cents per share.DICE Therapeutics’ average two-quarter negative earnings surprise is 163.28%.DICE Therapeutics, Inc. Price, Consensus and EPS Surprise DICE Therapeutics, Inc. price-consensus-eps-surprise-chart | DICE Therapeutics, Inc. QuotePliant Therapeutics Pliant Therapeutics is a clinical biotech focused on developing novel therapies for the treatment of fibrosis. The company has an Earnings ESP of +0.98% and a Zacks Rank #2. The Zacks Consensus Estimate for the second quarter is pegged at a loss of 82 cents per share.Pliant Therapeutics beat estimates in one of the last four quarters while missing in two and delivering in-line results in one. The company’s average earnings surprise is 0.90%. The company should release results this month.Pliant Therapeutics, Inc. Price, Consensus and EPS Surprise Pliant Therapeutics, Inc. price-consensus-eps-surprise-chart | Pliant Therapeutics, Inc. QuoteStay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want to Know the #1 Semiconductor Stock for 2022? Few people know how promising the semiconductor market is. Over the last couple of years, disruptions to the supply chain have caused shortages in several industries. The absence of one single semiconductor can stop all operations in certain industries. This year, companies that create and produce this essential material will have incredible pricing power. For a limited time, Zacks is revealing the top semiconductor stock for 2022. You'll find it in our new Special Report, One Semiconductor Stock Stands to Gain the Most. Today, it's yours free with no obligation.>>Give me access to my free special report.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Axcella Health Inc. (AXLA): Free Stock Analysis Report Pliant Therapeutics, Inc. (PLRX): Free Stock Analysis Report Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN): Free Stock Analysis Report Absci Corporation (ABSI): Free Stock Analysis Report DICE Therapeutics, Inc. (DICE): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksAug 9th, 2022

5 Sector ETFs That Show Promise After July Jobs Data

The U.S. economy added 528,000 jobs in July of 2022, breezing past market forecasts of 250,000 and above an upwardly revised 398,000 in June. The U.S. economy added 528,000 jobs in July of 2022, breezing past market forecasts of 250,000 and above an upwardly revised 398,000 in June, pointing to a solid jobs market. In July, the unemployment rate edged down to 3.5%, and the number of unemployed persons edged down to 5.7 million. The July jobs data marks larger than the average monthly gain over the prior four months (+388,000).Total nonfarm employment has increased by 22.0 million since hitting a trough in April 2020 and has returned to the pre-pandemic level. Private-sector employment is 629,000 higher than in February 2020, although several sectors have yet to recover. On the other hand, government employment is still 597,000 lower than its pre-pandemic level.Among the unemployed, the number of permanent job losers, at 1.2 million in July, continued to trend down over the month and is 129,000 lower than in February 2020. Below, we have highlighted some of the sectors that will likely see smooth trading in the days ahead in light of the July jobs data.LeisureLast month, leisure and hospitality employment grew by 96,000, thanks mainly to persistent growth in food services and drinking places (+41,000). Employment in leisure and hospitality is still down by 7.8% from February 2020.The data makes Invesco Dynamic Leisure and Entertainment ETF PEJ a timely investment. The fund has a Zacks Rank #3 (Hold) with a High risk outlook.HealthcareEmployment in the healthcare industry increased by 70,000 in July. Job gains occurred in ambulatory health care services (+47,000), hospitals (+13,000), and nursing and residential care facilities (+9,000). Employment in health care overall is below its February 2020 level by 78,000 or 0.5%. The Zacks Rank #1 fund Health Care Select Sector SPDR ETF XLV can be played to tap the momentum.TransportationEmployment in transportation and warehousing was decent in July (+21,000). Over the month, job gains continued in air transportation (+7,000) and support activities for transportation (+6,000). SPDR S&P Transportation ETF XTN has a Zacks Rank #2 with a High risk outlook.ManufacturingEmployment in manufacturing (+30,000) was upbeat in July. Employment in manufacturing decreased by 41,000 from its level in February 2020. Employment in durable goods industries rose by 21,000, with job gains in semiconductors and electronic components (+4,000) and miscellaneous durable goods manufacturing (+4,000). Industrial Select Sector SPDR ETF XLI has a Zacks Rank #2.ConstructionEmployment in construction rose by 32,000 in July. Construction employment is 82,000 higher than in February 2020. Invesco Dynamic Building & Construction ETF PKB can thus be considered for a play. Want key ETF info delivered straight to your inbox? Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week.Get it free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Industrial Select Sector SPDR ETF (XLI): ETF Research Reports Health Care Select Sector SPDR ETF (XLV): ETF Research Reports Invesco Dynamic Building & Construction ETF (PKB): ETF Research Reports Invesco Dynamic Leisure and Entertainment ETF (PEJ): ETF Research Reports SPDR S&P Transportation ETF (XTN): ETF Research Reports To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksAug 9th, 2022

Knight-Swift Transportation Holdings (KNX) is a Top-Ranked Value Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.The Style Scores are broken down into four categories:Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.How Style Scores Work with the Zacks RankThe Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.That's where the Style Scores come in.To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.Stock to Watch: Knight-Swift Transportation Holdings (KNX)Knight-Swift Transportation Holdings Inc. is the largest truckload carrier in North America. The company based in Phoenix, AZ, also provides transportation solutions and aims to grow through mergers and acquisitions. It serves customers throughout North America, providing them with numerous efficient and low-cost truckload transportation, intermodal and logistics services.KNX is a #2 (Buy) on the Zacks Rank, with a VGM Score of B.It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 10.09; value investors should take notice.For fiscal 2022, seven analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.05 to $5.39 per share. KNX boasts an average earnings surprise of 11.4%.With a solid Zacks Rank and top-tier Value and VGM Style Scores, KNX should be on investors' short list. Want to Know the #1 Semiconductor Stock for 2022? Few people know how promising the semiconductor market is. Over the last couple of years, disruptions to the supply chain have caused shortages in several industries. The absence of one single semiconductor can stop all operations in certain industries. This year, companies that create and produce this essential material will have incredible pricing power. For a limited time, Zacks is revealing the top semiconductor stock for 2022. You'll find it in our new Special Report, One Semiconductor Stock Stands to Gain the Most. Today, it's yours free with no obligation.>>Give me access to my free special report.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report KnightSwift Transportation Holdings Inc. (KNX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksAug 9th, 2022

Lear (LEA) is a Top-Ranked Value Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.The Style Scores are broken down into four categories:Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.How Style Scores Work with the Zacks RankThe Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +25.41% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.That's where the Style Scores come in.To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.Stock to Watch: Lear (LEA)Southfield, MI-based Lear Corporation is a Tier 1 supplier to the global automotive industry. The company supplies automotive seating and electrical systems (E-Systems). It caters to several major automakers in the world. The primary customers of the company are automotive original equipment manufacturers (OEMs). Lear’s products are designed, engineered and manufactured by a team of around 160,100 employees, located in 38 countries.LEA is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 17.19; value investors should take notice.For fiscal 2022, two analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.24 to $8.58 per share. LEA boasts an average earnings surprise of 14.4%.With a solid Zacks Rank and top-tier Value and VGM Style Scores, LEA should be on investors' short list. Want to Know the #1 Semiconductor Stock for 2022? Few people know how promising the semiconductor market is. Over the last couple of years, disruptions to the supply chain have caused shortages in several industries. The absence of one single semiconductor can stop all operations in certain industries. This year, companies that create and produce this essential material will have incredible pricing power. For a limited time, Zacks is revealing the top semiconductor stock for 2022. You'll find it in our new Special Report, One Semiconductor Stock Stands to Gain the Most. Today, it's yours free with no obligation.>>Give me access to my free special report.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Lear Corporation (LEA): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Category: topSource: zacksAug 9th, 2022

Giuliani denies buying airline tickets in dispute with Georgia prosecutors who just cited his travel receipts as the reason he needs to testify ASAP in their Trump investigation

Rudy Giuliani again professed ignorance about his travel arrangements amid a dispute with Georgia prosecutors over the timing of grand jury testimony. Former New York City Mayor Rudy Giuliani.Spencer Platt/Getty Images A dispute over Rudy Giuliani's grand jury testimony focused on whether he could travel to Georgia. Giuliani said a medical procedure prevented him from flying, but prosecutors cited travel receipts. Trump's personal lawyer denied buying airplane tickets and professed ignorance about the travel purchases. Rudy Giuliani on Tuesday denied purchasing plane tickets that local prosecutors in Georgia had cited in their bid to get the former New York City mayor's testimony before a grand jury investigating efforts by former President Donald Trump and his allies to reverse the state's 2020 election results.A week before his scheduled appearance before that grand jury, Giuliani said a recent medical procedure prevented him from traveling by plane and necessitated a delay of his testimony.But, in a new court filing, local prosecutors in the office of Fulton County District Attorney Fani Willis said they had obtained records showing that Giuliani paid in cash for multiple airline tickets — "including tickets to Rome, Italy, and Zurich, Switzerland" — for flights between July 22 and July 29.In a court filing Tuesday, Giuliani's lawyers said he had not traveled by plane to any location following his recent "surgical procedure.""First, and foremost, conspicuously absent from the state's pleading is the fact that no such travel ever occurred," wrote Giuliani's lawyer William Thomas Jr. "Secondly, Mr. Giuliani never purchased airline tickets in case, or otherwise."Thomas wrote that Giuliani had been invited to attend a conference overseas and said that, "presumably," the event organizers or some other third-party could have purchased tickets on his behalf — "but that is unknown to Mr. Giuliani or his counsel."During his travel overseas, Giuliani was scheduled to give a speech in Rome, his lawyer added. But Giuliani, "based solely on his health, canceled his speech in Rome," Thomas wrote in the court filing."Mr. Giuliani has no knowledge of anyone else purchasing tickets for him to travel to Rome, but in any event he did not go."The filing came just hours before a court hearing Tuesday — the same day Giuliani was set to appear before the grand jury — on his request to delay his testimony. It marked just the latest instance of Giuliani professing to lack knowledge about the planning and funding of his international travel.Last week, the New York Times reported that the company of Ukrainian oligarch Dmitry Firtash covered tens of thousands of dollars of Giuliani's travel expenses in the summer of 2019, a period federal investigators scrutinized during a criminal inquiry into his ties to Ukraine. The nearly three-year inquiry, which examined whether Giuliani illegally lobbied the Trump administration on behalf of Ukrainian officials, is unlikely to result in charges, the Times reported.While that investigation appears to be fading away, Giuliani is coming under intensifying scrutiny from the Fulton County district attorney's office. Giuliani has emerged as a key figure in that inquiry, in which local prosecutors are examining a now infamous phone call Trump made to Georgia's secretary of state, Brad Raffensperger, urging him to "find" enough votes to reverse his loss to then-President-elect Joe Biden.Giuliani was among the president's allies who participated in a scheme to create so-called alternate slates of pro-Trump electors in key battleground states the former president lost in 2020, including Georgia. Court filings have shown that Willis' office informed all 16 pro-Trump electors in Georgia that they could face charges in connection with the criminal investigation.Federal prosecutors have also been examining Giuliani's role in creating alternate slates of pro-Trump electors, and the House committee investigating the January 6, 2021, attack on the Capitol has highlighted his role spreading false conspiracy theories about the 2020 election.Read the original article on Business Insider.....»»

Category: dealsSource: nytAug 9th, 2022

Affiliated Managers Group (AMG) is a Top-Ranked Value Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Scores?The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.The Style Scores are broken down into four categories:Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.How Style Scores Work with the Zacks RankThe Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.#1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.That's where the Style Scores come in.You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only as a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.Stock to Watch: Affiliated Managers Group (AMG)Headquartered in Massachusetts, Affiliated Managers Group is a global asset manager with equity investments in a large group of investment management firms or affiliates.AMG is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.It also boasts a Value Style Score of A thanks to attractive valuation metrics like a forward P/E ratio of 6.98; value investors should take notice.For fiscal 2022, two analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.08 to $18.61 per share. AMG boasts an average earnings surprise of 3.8%.With a solid Zacks Rank and top-tier Value and VGM Style Scores, AMG should be on investors' short list. How to Profit from the Hot Electric Vehicle Industry Global electric car sales in 2021 more than doubled their 2020 numbers. And today, the electric vehicle (EV) technology and very nature of the business is changing quickly. The next push for future technologies is happening now and investors who get in early could see exceptional profits. See Zacks' Top Stocks to Profit from the EV Revolution >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Affiliated Managers Group, Inc. (AMG): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Category: topSource: zacksAug 8th, 2022

Why Huntington Bancshares (HBAN) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Scores?Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.The Style Scores are broken down into four categories:Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.How Style Scores Work with the Zacks RankA proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.#1 (Strong Buy) stocks have produced an unmatched +25.41% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.That's where the Style Scores come in.You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only as a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.Stock to Watch: Huntington Bancshares (HBAN)Headquartered in Columbus, OH, Huntington Bancshares Incorporated is a multi-state diversified regional bank holding company. Through its subsidiaries, including its banking subsidiary The Huntington National Bank, the company provides a comprehensive suite of banking, payments, wealth management, and risk management products and services.HBAN is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.Momentum investors should take note of this Finance stock. HBAN has a Momentum Style Score of B, and shares are up 9.6% over the past four weeks.Six analysts revised their earnings estimate upwards in the last 60 days for fiscal 2022. The Zacks Consensus Estimate has increased $0.04 to $1.46 per share. HBAN boasts an average earnings surprise of 0.9%.With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, HBAN should be on investors' short list. How to Profit from the Hot Electric Vehicle Industry Global electric car sales in 2021 more than doubled their 2020 numbers. And today, the electric vehicle (EV) technology and very nature of the business is changing quickly. The next push for future technologies is happening now and investors who get in early could see exceptional profits. See Zacks' Top Stocks to Profit from the EV Revolution >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Huntington Bancshares Incorporated (HBAN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksAug 8th, 2022

Welltower (WELL) to Report Q2 Earnings: What"s in the Cards?

Welltower's (WELL) Q2 earnings are likely to have benefited from occupancy gains in the seniors housing operating portfolio. However, higher expenses in the quarter might have been a deterrent. Welltower, Inc. WELL is slated to report second-quarter earnings on Aug 9, after market close. WELL’s quarterly results will likely highlight year-over-year growth in revenues and funds from operations (FFO) per share.In the last reported quarter, this Toledo, OH-based healthcare real estate investment trust (REIT) witnessed normalized FFO per share of 82 cents, in line with the Zacks Consensus Estimate. The seniors housing operating (SHO) portfolio average same-store occupancy witnessed a recovery during the quarter.Over the preceding four quarters, Welltower’s FFO per share beat the Zacks Consensus Estimate on two occasions and met the same in two, the average surprise being 1.27%. The graph below depicts this surprise history:Welltower Inc. Price and EPS Surprise Welltower Inc. price-eps-surprise | Welltower Inc. QuoteFactors at PlayWelltower’s SHO portfolio has been experiencing an improvement in move-in activity with manageable move-outs over the past few quarters. The widespread vaccination drives at assisted living and memory care facilities in the United States and the U.K. have reduced total resident case counts. As a result, Welltower’s communities have started to accept new residents.The SHO portfolio has witnessed a sizeable recovery, with average occupancy levels outpacing the pre-pandemic averages. This trend is likely to have continued through the second quarter. Per the July business update, the SHO portfolio spot occupancy expanded nearly 130 basis points (bps) during the second quarter, with a gain of roughly 50 bps during the last two weeks of June.While WELL’s U.K. SHO portfolio registered occupancy gains of roughly 410 bps during the quarter, its U.S. SHO portfolio reported the same at around 120 bps. In addition, the Canada SHO portfolio saw an occupancy gain of approximately 110 bps, with early-quarter momentum slowing down in June due to a rise in COVID-19 cases.The above-mentioned factors, coupled with the increased healthcare expenditure by the rapidly growing senior citizen population, are anticipated to have largely aided WELL’s SHO portfolio performance during the to-be-reported quarter.The Zacks Consensus Estimate for the second-quarter resident fees and services is pegged at $1.02 billion, indicating a 2.2% increase from the previous quarter’s $994 million. The consensus estimate for quarterly rental income stands at $356.2 million, implying a marginal rise from the prior-year quarter’s actuals.Welltower is expected to not only have benefited from growth in revenue per occupied room, which modestly exceeded expectations, but also from robust pricing power with strong recognized renewal rate increases and improving street rates during the quarter.Total revenues for the second quarter are pegged at $1.42 billion, suggesting a rise of 24.7% from the prior-year period’s reported number.Furthermore, Welltower has been focusing on strategic portfolio optimization and synergistic collaborations with health systems to invest in the next-generation assets of health and wellness care delivery. It also undertakes capital-recycling activities to finance near-term investment and development opportunities.Per its June business update, WELL had announced or completed nearly $750 million of new capital deployment since the release of its first-quarter earnings. Moreover, from the beginning of the year through Jun 6, 2022, it announced or completed $2.8 billion of capital deployment.In May, Welltower announced the expansion of its strategic partnership with Oakmont Management Group. It agreed to purchase seven senior living communities, subject to customary closing norms, which Oakmont will operate under an aligned RIDEA 3.0 contract.In June, concurrent with its business update, WELL announced the agreement with Calamar to purchase a 25-property senior apartment portfolio for $502 million. The transaction is likely to be funded by cash, the assumption of debt and UPREIT operating partnership units. Upon completion of the deal, WELL will significantly expand its market leadership with a total of nearly 10,000 units of Total Wellness Housing Platform.However, the commencement of the transition of 12 SHO properties, comprising 2,010 units, on the West Coast to three best-in-class existing WELL operating partners, that include Oakmont, Kisco, and Cogir, is likely to have led to higher expenses during the quarter. Further, a sequential decline in agency labor expenses in April and May was offset by higher expenses in June due to a rise in COVID-19 cases of staff members at certain properties. This might have acted as a deterrent for the quarter to be reported.The Zacks Consensus Estimate for the second-quarter FFO per share has moved downward by a penny to 85 cents over the past week. However, it implies an increase of 7.6% from the year-ago quarter’s reported figure.Earning WhispersOur proven model does not conclusively predict a surprise in terms of FFO per share for Welltower this season. The combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or higher — increases the odds of an FFO beat. However, that’s not the case here.Earnings ESP: Welltower has an Earnings ESP of -0.34%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Zacks Rank: WELL currently carries a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Performance of Other REITs Healthpeak Properties, Inc. PEAK reported second-quarter 2022 FFO as adjusted per share of 44 cents, surpassing the Zacks Consensus Estimate by a whisker. The reported figure was up 10% from the year-ago quarter’s 40 cents.PEAK’s performance was backed by solid top-line growth. However, weakness in the continuing care retirement communities portfolio was witnessed during the quarter.Ventas, Inc. VTR reported second-quarter 2022 normalized FFO per share of 72 cents, in line with the Zacks Consensus Estimate. The figure was a cent lower than the prior-year quarter’s tally.VTR’s results reflect growth in occupancy and improvement in pricing power for the senior housing operating portfolio. Additionally, the office portfolio witnessed growth in same-store net operating income while there was weakness in the triple-net leased portfolio.Mid-America Apartment Communities, Inc. MAA, commonly referred to as MAA, reported second-quarter 2022 core FFO per share of $2.02, surpassing the Zacks Consensus Estimate of $2.00. The reported number improved 19.5% year over year.This residential REIT’s quarterly results were driven by an increase in the average effective rent per unit for the same-store portfolio. MAA also increased its outlook for core FFO growth for the year.Note: Anything related to earnings presented in this write-up represent funds from operations (FFO) — a widely used metric to gauge the performance of REITs. How to Profit from the Hot Electric Vehicle Industry Global electric car sales in 2021 more than doubled their 2020 numbers. And today, the electric vehicle (EV) technology and very nature of the business is changing quickly. The next push for future technologies is happening now and investors who get in early could see exceptional profits. See Zacks' Top Stocks to Profit from the EV Revolution >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ventas, Inc. (VTR): Free Stock Analysis Report MidAmerica Apartment Communities, Inc. (MAA): Free Stock Analysis Report Welltower Inc. (WELL): Free Stock Analysis Report Healthpeak Properties, Inc. (PEAK): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksAug 8th, 2022